<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:chebi fb="2" ids="26536">Retinoic acid</z:chebi> (RA) is a powerful differentiation agent </plain></SENT>
<SENT sid="1" pm="."><plain><z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> occurs when duodeno-<z:e sem="disease" ids="C0017168" disease_type="Disease or Syndrome" abbrv="GERD">gastro-oesophageal reflux</z:e> causes squamous epithelium (SE) tissue to become columnar epithelium tissue by an unknown mechanism </plain></SENT>
<SENT sid="2" pm="."><plain>The <z:chebi fb="0" ids="3098">bile acid</z:chebi> <z:chebi fb="0" ids="16325">lithocholic acid</z:chebi> (LCA) competes for the <z:chebi fb="0" ids="26537">retinoid</z:chebi> X receptor <z:chebi fb="0" ids="26537">retinoid</z:chebi> binding site </plain></SENT>
<SENT sid="3" pm="."><plain>Hence, RA pathways may be implicated in <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>METHODS: RA activity in tissues and cell lines treated with <z:hpo ids='HP_0000001'>all</z:hpo>-trans <z:chebi fb="2" ids="26536">retinoic acid</z:chebi> (ATRA) with or without LCA was assessed using a reporter </plain></SENT>
<SENT sid="5" pm="."><plain>Expression of p21 was determined by real-time PCR in <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> cell lines with or without LCA </plain></SENT>
<SENT sid="6" pm="."><plain>SE and <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> biopsy specimens were exposed to 100 muM of ATRA or 20 mM of a RA inhibitor, <z:chebi fb="0" ids="23316">citral</z:chebi>, in organ culture for &gt;72 h </plain></SENT>
<SENT sid="7" pm="."><plain>Characteristics of treated specimens, compared with untreated controls, were analysed by immunohistochemical analysis (cytokeratins (CKs), vimentin) and RT-PCR (CKs) </plain></SENT>
<SENT sid="8" pm="."><plain>Confocal microscopy assessed temporal changes in co-localisation of CK8/18 and vimentin </plain></SENT>
<SENT sid="9" pm="."><plain>Cell proliferation was assessed by <z:chebi fb="1" ids="22927,47265">bromo</z:chebi>-deoxyuridine incorporation and immunohistochemical analysis for Ki67 and p21 </plain></SENT>
<SENT sid="10" pm="."><plain>RESULTS: RA biosynthesis was increased in <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> compared with SE (p&lt;0.001) </plain></SENT>
<SENT sid="11" pm="."><plain>LCA and ATRA caused a synergistic increase in RA signalling as shown by increased p21 (p&lt;0.01) </plain></SENT>
<SENT sid="12" pm="."><plain>Morphological and molecular analysis of SE exposed to ATRA showed columnar differentiation independent of proliferation </plain></SENT>
<SENT sid="13" pm="."><plain><z:mpath ids='MPATH_160'>Metaplasia</z:mpath> could be induced from the stromal compartment alone and vimentin expression co-localised with CK8/18 at 24 h, which separated into CK8/18-positive glands and vimentin-positive stroma by 48 h </plain></SENT>
<SENT sid="14" pm="."><plain><z:chebi fb="0" ids="23316">Citral</z:chebi>-treated <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> led to phenotypic and immunohistochemical characteristics of SE, which was independent of proliferation </plain></SENT>
<SENT sid="15" pm="."><plain>CONCLUSION: RA activity is increased in <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> and is induced by LCA </plain></SENT>
<SENT sid="16" pm="."><plain>Under conditions of altered RA activity and an intact stroma, the oesophageal phenotype can be altered independent of proliferation </plain></SENT>
</text></document>